This website is for UK Healthcare Professionals only

Contact us

Please complete the form below and a member of the BOTOX® (botulinum toxin type A) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.

BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.1

The BOTOX® (botulinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page. 

Please enter First name
Please enter Last name
E-mail address is not valid
Please enter Hospital name
Please enter Hospital postcode

Please select the items you are interested in:

Please select one field.

Please note that there may be certain circumstances where we contact you in relation to important AbbVie product information which we are required to provide to you or your patients as a matter of law, or in order to comply with the obligations we owe to you or them. This type of communication does not constitute promotional communication.

You can withdraw your consent at any time by using the unsubscribe option in the email or contacting [email protected]. For further information about AbbVie’s privacy practices, please refer to the AbbVie Privacy notice.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.



1. BOTOX® Summary of Product Characteristics. Available at: Accessed July 2023


Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.


Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to AbbVie on [email protected] 


Date of preparation: July 2023. UK-BUO-230052.